Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Pfizer Presses Case for AstraZeneca Deal Ahead of U.K. Hearing

May 13 (Bloomberg) -- Pfizer Inc. pressed its case for buying AstraZeneca hours before the chief executives of both companies are scheduled to appear before U.K. lawmakers to discuss Pfizer’s pursuit of the country’s second-biggest drugmaker.

In a presentation to AstraZeneca shareholders published today, Pfizer repeated its rationale for the deal, saying a deal would create an industry leader with scale and operational efficiency as well as a broader portfolio of experimental medicines. AstraZeneca faces challenges as a standalone company, including the declining revenue from products losing patent protection, Pfizer said.

The offer proposed by Pfizer on May 2, which AstraZeneca rejected as undervaluing the company, was based solely on public information, Pfizer said today in a statement. Talks between the companies would enable AstraZeneca’s management to provide Pfizer with a better understanding of the company, Pfizer said.

“Constructive engagement may lead to a transaction that AstraZeneca can recommend,” Pfizer said. “Pfizer will continue to be disciplined on price.”

Link to Company News:{AZN LN <Equity> CN <GO>} Link to Company News:{PFE US <Equity> CN <GO>}

To contact the editor responsible for this story: Kristen Hallam at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.